PT  - JOURNAL ARTICLE
AU  - Kojima, N
AU  - Klausner, JD
TI  - Usage and awareness of antiviral medications for COVID-19
AID  - 10.1101/2022.04.21.22274155
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.04.21.22274155
4099  - http://medrxiv.org/content/early/2022/04/26/2022.04.21.22274155.short
4100  - http://medrxiv.org/content/early/2022/04/26/2022.04.21.22274155.full
AB  - We surveyed people that recently tested positive for SARS-CoV-2 to assess the frequency and correlates of early treatment seeking behavior. Among high risk respondents, 66.0% were aware of treatment for COVID-19 and 36.3% had sought treatment, however only 1.7% reported use of an antiviral for SARS-CoV-2 infection. More public outreach is needed to raise awareness of the benefits of treatment for COVID-19.Competing Interest StatementNK is a consultant for Curative. JDK is an independent consultant and serves as the Medical Director of Curative.Funding StatementCurative Inc. and by a gift to the Keck School of Medicine of the University of Southern California by the W.M. Keck Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Advarra deemed the study IRB exempt (Pro00059961).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.